- Home
- CRDF vs CGEN Comparison
CRDF vs CGEN Comparison
Compare CRDF & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- CGEN
- Stock Information
- Founded
- CRDF 1999
- CGEN 1993
- Country
- CRDF United States
- CGEN Israel
- Employees
- CRDF N/A
- CGEN N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDF Health Care
- CGEN Health Care
- Exchange
- CRDF Nasdaq
- CGEN Nasdaq
- Market Cap
- CRDF 133.5M
- CGEN 142.8M
- IPO Year
- CRDF N/A
- CGEN 2000
- Fundamental
- Price
- CRDF $4.96
- CGEN $1.59
- Analyst Decision
- CRDF Strong Buy
- CGEN Strong Buy
- Analyst Count
- CRDF 3
- CGEN 2
- Target Price
- CRDF $10.33
- CGEN $4.00
- AVG Volume (30 Days)
- CRDF 3.9M
- CGEN 445.1K
- Earning Date
- CRDF 11-07-2024
- CGEN 11-12-2024
- Dividend Yield
- CRDF N/A
- CGEN N/A
- EPS Growth
- CRDF N/A
- CGEN N/A
- EPS
- CRDF N/A
- CGEN 0.02
- Revenue
- CRDF $688,000.00
- CGEN $59,852,000.00
- Revenue This Year
- CRDF $23.78
- CGEN $57.27
- Revenue Next Year
- CRDF N/A
- CGEN N/A
- P/E Ratio
- CRDF N/A
- CGEN $88.75
- Revenue Growth
- CRDF 49.57
- CGEN 698.03
- 52 Week Low
- CRDF $1.30
- CGEN $1.35
- 52 Week High
- CRDF $6.42
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- CRDF 72.82
- CGEN 51.01
- Support Level
- CRDF $3.06
- CGEN $1.55
- Resistance Level
- CRDF $5.64
- CGEN $1.68
- Average True Range (ATR)
- CRDF 0.45
- CGEN 0.08
- MACD
- CRDF 0.29
- CGEN 0.01
- Stochastic Oscillator
- CRDF 84.32
- CGEN 52.17
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.